Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2000

Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside T L, DeLeo A B

Abstract excerpt

Evidence has accumulated indicating that HLA-A2-restricted CTLs specific for human wild-type sequence p53 epitopes lyse tumor cells expressing mutant p53. To explore the possibility that wild-type sequence p53 peptides could also be used in vaccines for patients expressing HLA-A24 antigen, another frequent HLA class I allele, we investigated the induction of HLA-A24-restricted p53-specific CTLs from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding, Competitive
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Head and Neck Neoplasms

Share to HLA-A Antigens

Share to K562 Cells

Share to Oligopeptides

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 10741724

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.PMID 10741724Read ↗

Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53Semantic proximity Read ↗

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.Semantic proximity Read ↗

Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Semantic proximity Read ↗

A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.Semantic proximity Read ↗

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.Semantic proximity Read ↗

Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.Semantic proximity Read ↗

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.Semantic proximity Read ↗

CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

Wildtype p53-specific antibody and T-cell responses in cancer patients.Semantic proximity Read ↗

Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line.Semantic proximity Read ↗

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.Semantic proximity Read ↗

CD4+ T helper responses in squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.